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Background and purpose — The use of competing risks models 
is widely advocated in the arthroplasty literature due to a per-
ceived bias in comparison of simple Kaplan–Meier estimates. Pro-
ponents of competing risk models in the arthroplasty literature 
appear to be unaware of the subtle but important differences in 
interpretation of net and crude failure estimated by competing 
risk and Kaplan–Meier methods respectively.
Methods — Using a simple simulation we illustrate the differ-
ences between competing risks and Kaplan–Meier methods.
Results — Competing risk and Kaplan–Meier methods esti-
mate different survival quantities, i.e., crude and net failure 
respectively. Estimates of crude failure estimated using compet-
ing risk methods will be less than net failure as estimated using 
Kaplan–Meier methods.
Interpretation — Kaplan–Meier methods are appropriate for 
describing implant failure, whereas crude survival estimated 
using competing risk methods estimates the risk of surgical revi-
sion as it depends on both implant failure and mortality. Both 
competing risk models and Kaplan–Meier methods are useful 
in arthroplasty, and both provide unbiased estimates of crude 
and net failure in the absence of any confounding or selection 
respectively. Surgeons and researchers should carefully consider 
whether the use of competing risks is always justifi ed. Lower esti-
mates of failure from competing risk models may be misleading to 
surgeons who are attempting to select the best implants with the 
lowest failure rates for their patients.
■
We have recently noticed a number of incidences in the arthro-
plasty literature of authors espousing the benefi ts of using 
competing risk models in preference to Kaplan–Meier (KM) 
estimates to describe the failure of implants due to a percep-
tion that the observed high mortality rates in elderly patients 
may lead to biased estimates using the KM method (Biau et 
al. 2007, Fennema and Lubsen 2010, Keurentjes et al. 2012, 
Lacny et al. 2015, Porcher 2015, Wongworawat et al. 2015, 
Martin et al. 2016, Lampropoulou-Adamidou et al. 2017). 
This recent trend is somewhat worrying as we believe there is 
a fundamental misinterpretation of what Kaplan–Meier (KM) 
(Kaplan and Meier 1958) or competing risks (CR) (Coviello 
and Boggess 2004) models estimate, and under which circum-
stances each method may be preferable.
To correct this misunderstanding, we describe a simple 
simulation in a hypothetical situation with immortal patients, 
where no individuals are ever lost to follow-up. Figure 1 panel 
(a) illustrates this process using a line plot which illustrates 
when a patient becomes at risk and when a failure occurs and 
exits the study. In this situation, it is very easy to estimate 
implant survival at a time of interest, i.e., it is simply the 
proportion of those who fail. The numerator is the number 
of failures, and the denominator is the number of patients 
implanted. A simple proportion, KM estimates (Kaplan and 
Meier 1958), and the cumulative incidence function (CIF) 
(Coviello and Boggess 2004) from a CR model will give 
identical estimates. This scenario is the ideal scenario, as we 
need not concern ourselves with problems such as censor-
ing (loss to follow-up or mortality), and we describe these 
estimates of failure as net failure, using the terminology of 
Lambert et al. (2010).
However, some researchers are under the misguided belief 
that this hypothetical situation is the only scenario in which 
the KM estimator is appropriate (Biau et al. 2007). The title 
of Kaplan and Meier’s (1958) seminal work, “Nonparametric-
Estimation from Incomplete Observations,” gives us a clue to 
why this is incorrect. The KM method was specifi cally devel-
oped to allow incomplete observations due to non-informative 
right censoring, i.e., individuals cease to be at risk of failure, 
but have not failed where the reason that they cease to be at 
risk is completely independent of the cause of failure.
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In arthroplasty failure studies, mortality is one possible 
cause of being censored. Figure 1 panel (b) illustrates a non-
informative mortality profi le of patients in Figure 1 panel (a).
In this more complex and alternate situation with mortal 
patients, the failure process is more diffi cult to estimate due 
to the presence of a mortality process. This additional pro-
cess removes patients from the study and calculation of failure 
becomes more complex—see Figure 2 which overlays the fail-
ure and mortality processes.
Due to the complexity of this alternate situation with mortal 
patients, we are confronted with a choice of what to estimate. 
We can attempt to recover an estimate of net failure, which 
gives us an estimate of the failure of the implant, i.e., the fail-
ure estimate from the immortal cohort. Or, we can estimate 
crude failure, which represents the likely number of failures 
we see in practice, i.e., it is a composite of both the failure of 
the implants and the mortality process. The terminology used 
in this fi eld is somewhat heterogeneous, therefore we use the 
terminology described by Lambert et al. (2010).
Standard methods of conducting survival analysis, i.e., KM 
or Cox regression focus on net failure, are based solely on the 
hazard profi le of the cause of interest. Competing risk meth-
ods estimate crude failure and depend on both the hazard of 
the event of interest and the hazard of the competing event. 
The differences in the KM estimate with immortal patients 
and mortal patients and the CIF (competing risks estimate) 
with mortal patients is presented in Figure 3. Here, we simply 
create 2 independent random uniform failure profi les between 
0 and 10 years for 2 processes, (1) implant failure, and (2) 
mortality for 1,000 patients. Analysis of implant failure of 
immortal patients, ignoring the mortality process, can be 
considered the “truth,” and removing patients from the risk 
set due to a mortality event creates a mortal cohort, i.e., the 
observed. We expect the failure to be 100% at 10 years, and 
a straight line from 0 years to 10 years, i.e., a 45-degree line. 
This clearly illustrates the CIF (competing risks estimate) 
is not the same as that of KM. It is a biased estimate of net 
failure, but an unbiased estimate of crude failure. Whilst the 
simulation is extreme, i.e., everyone fails and everyone dies, 
the results will hold in all circumstances that the censoring 
is non-informative. The degree to which the CIF is different 
from the KM profi le depends on the mortality process. Prior 
to the fi rst mortality event, KM and CIF are equal, and only 
following the fi rst mortality event do they become unequal. 
In arthroplasty research differences between KM and CIF are 
likely to be more evident in series with long-term follow up, 
where mortality is inevitably higher, or in series with elderly 
or frail patients.
These differences are well known to those with a method-
ological interest in survival analysis. For example, Gooley et 
al. (1999) note that if one is interested in evaluating a cause-
specifi c failure, the CIF may be misleading and inferences 
should be made from functions which are based solely on the 
hazard of failure from the cause of interest, i.e., use the KM 
estimator. Putter et al. (2007) similarly state that the “naive 
Kaplan–Meier estimator describes what would happen if the 
competing event could be prevented to occur, creating an 
imaginary world in which an individual remains at risk of fail-
ure from the event of interest,” i.e., an immortal patient cohort. 
Ranstam et al. (2011) describe this in an arthroplasty setting 
as the “implicit assumption that the patient will be alive until 
the implant fails.” Recently, we have similarly illustrated this 
result using a simulation study in the context of prosthesis 
benchmarking: we illustrate that KM provides unbiased esti-
mates of net failure and provide nominal coverage, i.e., the 
confi dence interval includes the true value on 95% of occa-
sions (Sayers et al. 2017).
In as far as we currently know, the mortality process is inde-
pendent of whether implants are revised or not, i.e., mortal-
ity satisfi es the non-informative censoring assumption. Our 
Figure 1. Panel (a) is a line plot that illustrates the time at risk of 10 
patients entering a study following arthroplasty (time 0) and exiting the 
study after failure where the only possible mechanism of exiting the 
study is failure, i.e., no other cause of censoring occurs. Panel (b) is a 
line plot that illustrates a non-informative mortality profi le of the same 
10 patients entering a study following arthroplasty (time 0).
Figure 2. A line plot that illustrates 
the time at risk of 10 patients enter-
ing a study following arthroplasty 
(time 0) and the combination of a 
failure and mortality mechanism, 
i.e., mortal patients.
Figure 3. KM survival curves 
and the 1 minus the cumulative 
incidence function in mortal and 
immortal cohorts.
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belief in this assumption is based on the observation that even 
when an implant or group of implants fail in a large number of 
patients, e.g., metal on metal, this is not associated with any 
increase in pathologies, in the short term, such as cancer that 
in turn may lead to an excess of mortality (Smith et al. 2012a, 
2012b, 2012c). However, it is important these assumptions are 
checked periodically; an absence of evidence is not evidence 
of absence, and future information may require analyses to be 
modifi ed to account for an informative censoring profi le. 
Simply, competing risk methods and non-competing risk 
methods estimate different quantities, and which quantity you 
should use depends on your application of interest. If you are 
interested in describing the failure of an implant, comparing 
the failure rate of a group of implants, looking for outliers, 
i.e., from a regulatory perspective, or attempting to select an 
implant for use that has the greatest longevity, you need esti-
mates of net failure (KM). If you are interested in resource 
planning, health economics, or communicating with patients 
their likely chance of experiencing a revision, estimates of 
crude failure (CR) are more likely to be desirable. 
Just because the estimate of net implant failure is higher 
than crude failure does not mean they are not correct or desir-
able in many circumstances in arthroplasty. However, it also 
important to remember that whilst KM and the CIF are sta-
tistically unbiased estimates for net and crude failure respec-
tively, they are both equally likely to display bias in the pres-
ence of confounding factors and selection effects, and simply 
choosing the appropriate approach is not a panacea against 
this immutable problem. 
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